Atrium Therapeutics, Inc.

NASDAQ:RNA

Biotechnology

Healthcare
$6.64 +1.28%

+$0.16 today

Market cap
$143.23M
Beta
0.42
P/E (TTM)
-3.3
EPS (TTM)
-$3.78
52W Low $11.40High $16.77

Volume 0.22M

Average 0.35M

RNA Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

Atrium Therapeutics, Inc.NASDAQ: RNA

Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026

Deferred revenue of $9.34M in Q1 FY2026

Q1 FY2026 deferred revenue was $9.34M.

Context

  • Deferred revenue amounted to 3.2% of total assets at the end of Q1 FY2026.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.34M-56.8% QoQ
Last fiscal yearDec 2025
$21.64M— YoY
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Revenue history

USD · from the balance sheet

Latest · FY2025
21.64M USD
Year-over-year change
—

Deferred Revenue vs competitors

How RNA compares with its peers on the latest reported figures

No competitor Deferred Revenue figures are available to compare.

Atrium Therapeutics, Inc.

NASDAQ:RNA

Intrinsic Alpha fair value

Locked

Current Price

$6.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.